Related Experiment Video

Updated: Jun 29, 2025

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.1K

A Mechanism for the Treatment of Cardiovascular and Renal Disease: TRPV1 and TRPA1

Lu Gao1, Qi Wang, Min-Yi Li

  • 1School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, China.

Journal of Cardiovascular Pharmacology
|March 28, 2024
PubMed

Insights

Transient Receptor Potential Vanilloid 1 (TRPV1) and Transient Receptor Potential Ankyrin 1 (TRPA1) channels are crucial in managing cardiovascular and kidney diseases. Understanding their mechanisms offers new therapeutic avenues for cardiorenal conditions.

Area of Science:

  • Cardiovascular Science
  • Nephrology
  • Molecular Biology
  • Ion Channel Physiology

Background:

  • Cardiovascular disease (CVD) is a leading global cause of death.
  • Kidney injury significantly increases CVD mortality, highlighting the cardiorenal link.
  • Complex signaling pathways underlie cardiorenal diseases, with ion channels gaining attention.

Purpose of the Study:

  • To investigate the role of Transient Receptor Potential Vanilloid 1 (TRPV1) and Transient Receptor Potential Ankyrin 1 (TRPA1) channels in cardiovascular and renal diseases.
  • To analyze the mechanisms by which TRPV1/TRPA1 channels influence cardiorenal pathophysiology.
  • To provide a foundation for novel therapeutic strategies targeting TRPV1/TRPA1 in cardiorenal conditions.

Main Methods:

  • Literature review and analysis of existing research on TRPV1 and TRPA1 channels.
  • Examination of the involvement of TRPV1/TRPA1 in regulating vascular tension, angiogenesis, fibrosis, inflammation, and oxidation.
  • Exploration of the molecular mechanisms, including intracellular calcium influx and release of nitric oxide and calcitonin gene-related peptide.

Main Results:

  • TRPV1/TRPA1 channels are integral to cardiorenal disease pathogenesis.
  • These channels modulate key physiological processes including vascular tone and inflammation.
  • Mechanisms involve calcium signaling and the release of vasoactive and anti-inflammatory mediators.

Conclusions:

  • TRPV1/TRPA1 channels represent a significant therapeutic target for cardiorenal diseases.
  • Further research into TRPV1/TRPA1 mechanisms can lead to improved treatments for conditions affecting both the heart and kidneys.
  • Understanding these ion channels is vital for addressing the high morbidity and mortality associated with cardiorenal diseases.

More Related Videos

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

8.2K
Expression and Purification of the Human Lipid-sensitive Cation Channel TRPC3 for Structural Determination by Single-particle Cryo-electron Microscopy08:27

Expression and Purification of the Human Lipid-sensitive Cation Channel TRPC3 for Structural Determination by Single-particle Cryo-electron Microscopy

Published on: January 7, 2019

9.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Mechanically-gated Ion Channels01:12

Mechanically-gated Ion Channels

Mechanically-gated ion channels are proteins found in eukaryotic and prokaryotic cell membranes that open in response to mechanical stress. Tension, compression, swelling, and shear stress can alter the conformation of the protein, opening a transmembrane channel that allows the passage of ions for signal transmission. In eukaryotes, mechanically-gated channels are distributed in several regions like the neurons, lungs, skin, bladder, and heart, where they play critical roles in numerous...
6.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162